Please check your internet connection and try again.
# Pantoprazole (Protonix)
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available in oral (delayed-release tablet, suspension) and intravenous (IV) formulations.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Short-term treatment of GERD (off-label/commonly used for stress ulcer prophylaxis in ICU settings).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg daily have been used; adjust based on gastric acid output.
* **Stress Ulcer Prophylaxis (ICU):** 40 mg IV daily.
## Pediatric Dosing
* **Erosive Esophagitis (5 years and older):**
* 15 kg to <40 kg: 20 mg PO once daily for up to 8 weeks.
* 40 kg and greater: 40 mg PO once daily for up to 8 weeks.
* **Note:** IV dosing for pediatrics is not standard and should be avoided unless specified by institutional protocol.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:** No strict adjustment required by labeling, but consider lowering frequency or dose in severe hepatic impairment (Child-Pugh C) due to potential accumulation.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Concurrent use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous lupus erythematosus, and increased risk of osteoporosis-related fractures with chronic high-dose therapy.
## Key Drug Interactions
* **pH-dependent drugs:** May decrease absorption of ketoconazole, atazanavir, and iron salts.
* **Methotrexate:** PPIs may increase methotrexate levels (monitor closely, especially in high-dose therapy).
* **Clopidogrel:** Potential reduced antiplatelet effect of clopidogrel; clinical significance is debated, but consider switching to a different PPI if interaction is suspected.
## Monitoring
* Monitor for symptom resolution.
* Monitor magnesium levels if on long-term therapy or concomitant diuretics.
* Monitor for signs of *C. difficile* infection (unexplained persistent diarrhea).
* For hypersecretory conditions: Monitor gastric acid output.
## Clinical Pearls
* **Administration:** Tablets should be swallowed whole; do not crush or chew. May be administered with or without food.
* **IV Administration:** Must be administered as an IV pinch or continuous infusion per institutional policy; flush line before and after.
* **Deprescribing:** Long-term PPI use should be periodically evaluated to ensure clinical necessity. Tapering may be required to avoid rebound acid hypersecretion during discontinuation.
***
**Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary. Always verify current prescribing information, institutional guidelines, and patient-specific factors before administering medication.
